This site is intended for healthcare professionals

ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

BUPRENEX
Narcotic analgesics
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

BUPRENEX CIII

Generic Name and Formulations:
Buprenorphine (as HCl) 0.3mg/mL; for IM or IV inj.

Company:
Reckitt Benckiser Pharmaceuticals, Inc.

Therapeutic Use:

Indications for BUPRENEX:

Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Adult:

Use lowest effective dose for shortest duration. Individualize. >12yrs: initially 0.3mg (1mL) by deep IM or slow IV (over ≥2mins) inj at up to 6hr intervals, as needed. May repeat once (up to 0.3mg), 30–60mins after initial dose. Max single dose: 0.6mg (IM only). Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).

Children:

<2yrs: not recommended. 2–12yrs: 2–6micrograms/kg every 4–6hrs, depending on clinical response. Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).

Contraindications:

Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.

Warnings/Precautions:

Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). History of long QT syndrome; avoid. Hypokalemia, hypomagnesemia, unstable cardiac disease (eg, unstable atrial fibrillation, symptomatic bradycardia, unstable CHF, active MI); monitor ECG periodically. Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Myxedema or hypothyroidism. Toxic psychoses. Prostatic hypertrophy. Urethral stricture. Delirium tremens. Kyphoscoliosis. Drug or alcohol abusers. Severe pulmonary, hepatic, or renal impairment. Reevaluate periodically. Avoid abrupt cessation. Children. Elderly. Cachectic. Debilitated. Labor & delivery. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Nursing mothers: not recommended.

Interactions:

Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. Avoid concomitant Class 1A (eg, quinidine, procainamide, disopyramide) or Class III antiarrhythmics (eg, sotalol, amiodarone, dofetilide). During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist and partial agonist opioids (eg, butorphanol, nalbuphine, pentazocine); may reduce effects and precipitate withdrawal symptoms. Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, protease inhibitors). Antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics. Chronic Buprenex treatment with concomitant NNRTIs (eg, efavirenz, nevirapine, etravirine, delavirdine); monitor. Concomitant atazanavir ± ritonavir: may need to reduce Buprenex dose.

Pharmacological Class:

Opioid (partial agonist-antagonist).

Adverse Reactions:

Sedation, dizziness/vertigo, nausea, vomiting, hypotension, miosis, headache, sweating, hypoventilation; respiratory depression, severe hypotension, syncope, hypersensitivity reactions.

How Supplied:

Amps (1mL)—5

Join MIMS Learning now to manage all your CPD and notes in one place!

By registering you agree with our Terms and Conditions and Privacy Policy.


Already a MIMS Learning member?

Sign In Now »
Red flag CPD modules
0.50 Credits
Red flags

Fever in adults - red flag symptomsExternal web site

Fever in adults can have potentially serious causes, ranging from sepsis to malignancy. Dr Pipin Singh...

0.50 Credits
Red flags

Bone pain - red flag symptomsExternal web site

In this article Dr Pipin Singh advises on how to identify red flags in patients presenting with bone...

0.50 Credits
Red flags

Pregnancy - red flag symptomsExternal web site

Dr Matthew West covers the red flags to look out for in pregnancy, including back pain, bleeding, headaches...

Font Awesome Icons
View more
Clinical review CPD modules
1.50 Credits
Clinical Review

Bronchiectasis: clinical reviewExternal web site

This article, updated in 2016 by Dr Anthony De Soyza, advises on causes, investigations and managing...

1.50 Credits
Clinical Review

Brugada syndrome: clinical reviewExternal web site

Dr Keith Barnard discusses the aetiology and symptoms of Brugada syndrome. Key learning points for GPs...

1.50 Credits
Clinical Review

Measles: clinical reviewExternal web site

Dr Kirsty Le Doare and Dr Nuria Martinez-Alier describe the signs and symptoms of measles and outline...

Font Awesome Icons
View more

is free, fast, and customized just for you!

Already a member?

Sign In Now »